Jan 8, 2026, 11:29 GMT+7
By Bharath Rajeswaran and Vivek Kumar M
Reuters - Indian shares were headed for a fourth straight session of declines on Thursday amid cautious sentiment, with U.S. tariff worries and foreign fund outflows overshadowing optimism over earnings growth.
The Nifty 50fell 0.18% to 26,093.35, while the Sensextraded 0.13% lower at 84,847.3, as of 9:55 a.m. IST.
Fifteen of the 16 major sectors fell. The broader small-capsand mid-capsslipped 0.2% and 0.4%, respectively.
The Nifty 50 index has fallen 0.7% in the last three sessions, and the Sensex lost 0.9%, after U.S. President Donald Trump warned of higher tariffs on Indian goods over Russian oil purchases, even as New Delhi seeks a trade deal with Washington.
The U.S. has already imposed tariffs of up to 50% on Indian goods, with half of those penalties tied to New Delhi's Russian crude imports.
Meanwhile, foreign investors sold Indian shares worth 15.28 billion rupees ($170.26 million) on Wednesday, provisional data showed. They have offloaded $694 million worth of shares so far in January after record outflows in 2025.
"Geopolitics and global trade have cast a shadow of chronic risk aversion for equity markets," said analysts led by Abhishek Saraf of Motilal Oswal Financial Services.
The conclusion of the long-pending India-U.S. bilateral trade deal will be a key catalyst for an upside move in Indian markets, they added.
Metal indexdeclined 1.9% with all 15 constituents logging losses, as the global metals rally lost steam. The sectoral sub-index had hit a record high on Tuesday.
IT indexfell 1% after gaining 2.4% in the last two sessions.
Among stocks, Gland Pharmaclimbed 2% after receiving the U.S. drug regulator's approval for Olopatadine solution aimed at treating ocular itching and allergic conjunctivitis.
Balaji Aminesjumped 9% after the Maharashtra government granted an eligibility certificate for unit expansion, making the company eligible for industrial subsidies worth 2.58 billion rupees.
($1 = 89.7450 Indian rupees)
Sumber : Reuters
Reprinted from indopremier_id,the copyright all reserved by the original author.
Disclaimer: The views expressed are solely those of the author and do not represent the official position of Followme. Followme does not take responsibility for the accuracy, completeness, or reliability of the information provided and is not liable for any actions taken based on the content, unless explicitly stated in writing.
Like this article? Show your appreciation by sending a tip to the author.

Leave Your Message Now